|
DEVELOPMENT FEATURES OF PHARMACEUTICAL INDUSTRY AND ITS ROLE IN SECURING THE FUTURE DEVELOPMENT OF RUSSIAN ECONOMY |
|---|---|
| รหัสดีโอไอ | |
| Creator | Mintimer Vagizovich Mingazov, Aydar M. Tufetulov, Gulnara Nasimovna Khadiullina |
| Title | DEVELOPMENT FEATURES OF PHARMACEUTICAL INDUSTRY AND ITS ROLE IN SECURING THE FUTURE DEVELOPMENT OF RUSSIAN ECONOMY |
| Contributor | - |
| Publisher | TuEngr Group |
| Publication Year | 2562 |
| Journal Title | International Transaction Journal of Engineering, Management, & Applied Sciences & Technologies |
| Journal Vol. | 10 |
| Journal No. | 19 |
| Page no. | 10A19O: 1-8 |
| Keyword | Pharmaceutical industry, National security, Medical devices, Innovative activities, Medicines, Targeted state programs. |
| URL Website | http://tuengr.com/Vol10_19.html |
| Website title | ITJEMAST V10(19) 2019 @ TuEngr.com |
| ISSN | 2228-9860 |
| Abstract | The article examines the factors of competitive potential and the risks of the development of the pharmaceutical industry in the modern Russian economy, its impact on the state of national security and the dynamics of the main macroeconomic indicators. The aim of the study is to identify tools to control the sources of competitive advantages of Russian pharmaceutical companies in order to increase their level of competitiveness in the domestic and foreign markets, enhance their innovative activities. The article uses the general scientific and specific methods to analyze the state of the pharmaceutical industry and the pharmaceutical industry as its component. the SWOT analysis identifies the strengths and weaknesses of the internal and external environment of Russian pharmaceutical companies, opportunities and development risks, and also formulate recommendations regarding the directions of strategic development of manufacturers of medicines and medical devices. Particular attention is paid to the analysis of the provisions of the state program "Development of the pharmaceutical and medical industry for 2013-2020" ("Pharma-2020") providing for the implementation of measures of state regulation of the pharmaceutical industry, including measures to stimulate investment and innovation activity, the adjustment of compliance control tools produced standards, the introduction of information and communication technologies in the process of monitoring the promotion of drugs NNYH funds on the market, the formation of integrated structures (pharmaceutical clusters) and innovation infrastructure. |
